| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
Dacarbazine (formerly also known as DTIC, DTIC-Dome; WR-139007; Asercit; Dacatic; Deticene) is an antitumor chemotherapeutic drug approved by FDA in the 1970s for the treatment of various cancers, including advanced melanoma (major use), Hodgkin lymphoma, sarcoma, and islet cell carcinoma of the pancreas. Dacarbazine treatment activates a Fas-independent pathway that makes melanomas more susceptible to peptide-specific CTL lysis. Dacarbazine is a member of the class of agents known as DNA-alkylating agents, which alter the DNA of cancer cells by introducing an alkyl group.
| Targets |
Nucleoside antimetabolite/analog
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Cell Assay |
Apotosis assay: UACC903 (UACC) cells treated with or without DTIC (20 μM) for 48 hours are incubated for 5 and 16 hours, respectively, with agonist anti-Fas Ab, CH-11 (500 ng/ml). In order to determine whether FasR mediates death or apoptosis, blocking anti-Fas Ab ZB4 (2 mg/ml) is added to the appropriate groups. Following the company's instructions, cells are harvested at the conclusion of the incubation period and stained with propidium iodide and FITC-annexin V (BD PharMingen) to identify apoptosis. Ten thousand cells are taken from each group, and CellQuest software is used to analyze dead and apoptotic cells without gating.
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C6H10N6O
|
|
|---|---|---|
| Molecular Weight |
182.18
|
|
| Exact Mass |
182.09
|
|
| Elemental Analysis |
C, 39.56; H, 5.53; N, 46.13; O, 8.78
|
|
| CAS # |
4342-03-4
|
|
| Related CAS # |
|
|
| Appearance |
White solid powder
|
|
| SMILES |
CN(C)/N=N/C1=C(NC=N1)C(=O)N
|
|
| InChi Key |
FDKXTQMXEQVLRF-ZHACJKMWSA-N
|
|
| InChi Code |
InChI=1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+
|
|
| Chemical Name |
4-[(E)-dimethylaminodiazenyl]-1H-imidazole-5-carboxamide
|
|
| Synonyms |
DTIC-Dome; WR139007; Biocarbazine; Dacarbazine; DTIC; Dakarbazin; WR 139007; WR-139007; US trade name: DTICDome. Foreign trade names: Asercit; Dacatic; Deticene; Detimedac; Fauldetic.
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2 mg/mL (10.98 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
Solubility in Formulation 2: 5 mg/mL (27.45 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: 0.5% CMC Na : 30mg/mL |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4891 mL | 27.4454 mL | 54.8908 mL | |
| 5 mM | 1.0978 mL | 5.4891 mL | 10.9782 mL | |
| 10 mM | 0.5489 mL | 2.7445 mL | 5.4891 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03016819 | Active Recruiting |
Drug: AL3818 Drug: Dacarbazine |
Leiomyosarcoma Synovial Sarcoma |
Advenchen Laboratories, LLC | August 15, 2017 | Phase 3 |
| NCT05269355 | Active Recruiting |
Drug: Dacarbazine Other: Placebo |
Leiomyosarcoma | PTC Therapeutics | May 23, 2022 | Phase 2 Phase 3 |
| NCT03233347 | Active Recruiting |
Drug: Dacarbazine Drug: Doxorubicin |
Ann Arbor Stage I Hodgkin Lymphoma Classic Hodgkin Lymphoma |
Academic and Community Cancer Research United |
October 13, 2017 | Phase 2 |
| NCT02076646 | Active Recruiting |
Drug: L19IL2 - Ph I Drug: L19IL2 at RD - Ph II |
Metastatic Melanoma Stage IV | Philogen S.p.A. | July 31, 2013 | Phase 1 Phase 2 |
| NCT03023124 | Recruiting | Drug: Dacarbazine Drug: Adriamycin |
Solitary Fibrous Tumors | Italian Sarcoma Group | March 4, 2018 | Phase 2 |
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
